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Abstract
Context: Type 2 diabetes is associated with cerebral atrophy, cognitive impairment and dementia. We recently showed
higher glucose levels in the normal range not to be free of adverse effects and to be associated with greater hippocampal
and amygdalar atrophy in older community-dwelling individuals free of diabetes.
Objective: This study aimed to determine whether blood glucose levels in the normal range (,6.1 mmol/L) were associated
with cerebral volumes in structures other than the hippocampus and amygdale, and whether these glucose-related regional
volumes were associated with cognitive performance.
Design, Setting and Participants: 210 cognitively healthy individuals (68–73 years) without diabetes, glucose intolerance or
metabolic syndrome were assessed in the large, community-based Personality and Total Health Through Life (PATH) study.
Main Outcome Measure: Baseline blood glucose levels in the normal range (3.2–6.1 mmol/l) were used to determine
regional brain volumes and associated cognitive function at wave 3.
Results: Higher blood glucose levels in the normal range were associated with lower grey/white matter regional volumes in
the frontal cortices (middle frontal gyrus, inferior frontal gyrus precentral gyrus). Moreover, identified cerebral regions were
associated with poorer cognitive performance and the structure-function associations were gender specific to men.
Conclusion: These findings stress the need to re-evaluate what is considered as healthy blood glucose levels, and consider
the role of higher normal blood glucose as a risk factor for cerebral health, cognitive function and dementia. A better
lifetime management of blood glucose levels may contribute to improved cerebral and cognitive health in later life and
possibly protect against dementia.
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Introduction
It is well established that type 2 diabetes is associated with
‘accelerated brain ageing’ [1], white matter lesions [2], atrophy
[3,4] and the presence of infarcts [5], which in turn relate to
reduced cognitive functioning [1,4], an increased risk of
Alzheimer’s disease [6,7] and vascular damage [8]. A review by
Awad et al. [9] of the relationship between impaired glucose
tolerance, type 2 diabetes and cognitive function highlighted
research linking sub-clinical levels of glucose in the high-normal
range for glucose tolerance or impaired glucose tolerance (fasting
glucose levels ,7 mmol/L) with cognitive function, smaller
hippocampal volumes and poor glucose regulation [10]. Notably,
research has shown a decrement in cognitive function associated
with impaired glucose tolerance in men, while women appear to
demonstrate virtually identical scores to normoglycaemic women
[11].
We have recently shown that higher glucose levels in the normal
range (,6.1 mmol/L) are not necessarily free of adverse effects,
and are associated with greater hippocampal and amygdalar
atrophy in older community-dwelling individuals free of diabetes
[12]. These findings are in accordance with animal studies
demonstrating higher plasma glucose levels in rats to be associated
with hippocampal neuronal loss, decreased neurogenesis, impaired
spatial learning, reduced hippocampal dendritic spine density, and
reduced long-term potentiation [13–15]. Furthermore, in non-
diabetics, experimentally raised plasma glucose levels have been
associated with increased systemic inflammation [16,17], abnor-
mal coagulation function [18], chronic stress and activation of the
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Hypothalamus-Pituitary-Adrenal axis [19], which are possible
mechanisms that may explain these findings.
What is not known is whether glucose levels in the normal range
are associated with cerebral volumes in structures other than the
hippocampus and amygdala, and whether glucose-related regional
volumes are associated with cognitive function. The aim of this
study therefore was to assess whether blood glucose levels in the
normal range (,6.1 mmol/L) are associated with volumes of other
brain regions and to determine whether there is an association
between these glucose-related regions and cognitive function in a
large cohort of community-based individuals free of diabetes or
cognitive impairment [20].
Materials and Methods
Ethics Statement
All participants gave written informed consent to be included in
the Personality and Total Health (PATH) project. The study was
approved by the Human Research Ethics Committee of The
Australian National University.
Subjects
Subjects were sampled from the Personality and Total Health
Through Life (PATH) project, a large longitudinal study of ageing
aimed at investigating the course of mood disorders, cognition,
health and other individual characteristics across the lifespan [20].
PATH surveys 7485 individuals in three age groups of 20–24, 40–
44 and 60–64 years at baseline. Follow-up is every four years over
a period of 20 years. PATH surveys residents of the city of
Canberra and the adjacent town of Queanbeyan, Australia, who
were randomly recruited through the electoral roll [20]. Enrol-
ment to vote is compulsory for Australian citizens, making this
cohort representative of the population. The study was approved
by the Australian National University Ethics Committee.
The present investigation is focused on the older participants
(60 s cohort). Of the 2551 randomly selected older PATH subjects
included in the study at wave 1, 2076 consented to be contacted
regarding an MRI scan. Of these, a randomly selected subsample
of 622 subjects was offered an MRI scan. 478 (77%; 252 men)
eventually completed MRI scanning. Of these, 360 subjects (198
men; age range 68–74) were rescanned at wave 3. Of those with
MRI scans, fifty-four (15%) were excluded from the current
analyses as no blood glucose levels had been obtained at baseline.
Fifty-six (18%) were excluded from the current analyses due to
gross brain abnormalities (e.g. tumours, hydrocephalys; n = 18), a
history of epilepsy, Parkinson’s disease or stroke (n = 20), or a
clinical diagnosis of any form of cognitive dysfunction (e.g.
vascular dementia, mild cognitive impairment; n = 18). A further
40 subjects were excluded from the current analyses based on
baseline blood glucose level above 6.1 mmol/L (110 mg/dl;
n = 22) or a history of diabetes (n = 18) (Figure 1). A cut off of
blood glucose levels above 6.1 mmol/L was used in accordance
with the World Health Organisation threshold for impaired fasting
hyperglycaemia (6.1 mmol/L, 110 mg/dl). This excluded individ-
uals with diabetes, sub-clinical diabetes or glucose intolerance and
ensured that the effect detected was not due to clinical or sub-
clinical glucose metabolism abnormalities.
Following all exclusions, the final sample included 210
participants with glucose levels ranging between 3.2 and
6.1 mmol/l– a range considered to be representative of normal
blood glucose levels. The final sample did not differ from the larger
PATH sample on gender (x2 (1, N=2551) = 0.139, p=0.710), but
had completed significantly more years of education (14.4 vs 13.7;
t (2544) =23.31, p,0.001).
Socio-demographic and health measures
Socio-demographic information for race, years of education,
alcohol consumption, smoking and depression were assessed using
self-report. Body mass index (BMI) was based on subjects’ self-
report of weight and height and computed using the formula
weight (kg)/height (m)2. The Alcohol Use Disorder Identification
Test (AUDIT) was used to assess alcohol intake [21]. ‘For men,
weekly alcohol consumption was categorized as light (1–13 units),
moderate (14–27 units), hazardous (28–42 units) or harmful
(.42 units). For women, weekly alcohol consumption was divided
into light (1–7 units), moderate (8–13 units), hazardous (14–
28 units) or harmful (.28 units) categories where a unit equates
10 g of pure alcohol’ [12].
Blood glucose measures
Venous blood was collected at baseline following an overnight
fast of at least 10 hours. Plasma and Serum aliquots were frozen at
280uC. Fasting plasma glucose was measured on a Beckman
LX20 Analyzer by an oxygen rate method (Fullerton, California)
[12].
Neuropsychological tests
Cognitive performance was assessed at wave 3. All participants
completed all cognitive assessments as part of the standardised
procedure for test administration (same order of test administra-
tion for each participant). To avoid possible interaction effects
between cognitive assessments the neuropsychological tests were
separated by physical measure assessments (e.g. measuring of
blood pressure, waist circumference or lung capacity).
Verbal working memory was assessed through the Digit Span
Backwards (DSB) – a subtest of the Wechsler memory scale [22].
In the DSB participants were read numbers at one-second
intervals. When participants incorrectly repeated both trials no
further trials were given. Information and processing speed were
assessed using the Symbol-Digit Modalities Test (SDMT) [23].
Participants were given 90 seconds to complete this task. Episodic
memory was assessed using the first trial of the California Verbal
Learning Test for both immediate (IRT) and delayed recall (DRT)
[24]. Participants were read words at one second intervals and
there was approximately one minute between immediate and
delayed recall tests. Participants were not limited in the amount of
time they could take to recall at either trial. The Boston Naming
Test (BNT) [25] was used to assess language function. Participants
were shown pictures of objects and asked to name the object.
Executive function of verbal fluency was assessed using the
Controlled Oral Word Association Test (COWAT) for both A-
and F-words. Participants were timed for 60 seconds to list as
many words starting with the letters A and F respectively.
Data Acquisition
MRI scans used in this study were taken at wave 3. Subjects
were scanned on a Siemens 1.5T Avanto scanner (Siemens
Medical Solutions) for T1-weighted three-dimensional structural
MRI. The T1 weighted MRI was acquired in sagittal orientation
using the following parameters: repetition time (TR)/echo time
(TE) = 1.16/,0.8 ms; flip angle = 15u; matrix size = 5126512;
slice thickness = 1.0 mm; resulting in a final voxel size of
160.560.5 mm.
Image Processing
All images were pre-processed using the MINC imaging toolbox
(MINC; http://en.wikibooks.org/wiki/MINC), images went
through automatic QC to identify outliers via image histogram
PATH: High Normal Blood Glucose and the Brain
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e73697
clamping and comparisons to the group minimum deformation
average [26]. Images were then B0 MRI inhomogeneity corrected
using N3 [27], and normalised via a linear correction to a global
intensity model [26].
Optimized voxel-based morphometry (VBM) analyses were
conducted using Statistical Parametric Mapping 8 (SPM8; Well-
come Department of Cognitive Neurology, London, UK, 2003) on
Matlab 7.12 (Math Works, Natick, MA, USA, 2002). Images were
first segmented into grey matter, white matter and cerebrospinal
Figure 1. Sample Inclusion.
doi:10.1371/journal.pone.0073697.g001
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fluid [28]. Grey and white matter segmentations were further
normalized to the sample template (population representative)
which was generated by the diffeomorphic anatomical registration
through exponentiated lie algebra (DARTEL) algorithm from
participants’ complete images [29]. DARTEL is a nonlinear
warping technique that minimizes structural variation between
subjects and has been evidenced to be more accurate than the
standard normalization approach in SPM [30,31]. Briefly,
segmented images were registered, normalised and modulated to
fit the DARTEL space, creating a DARTEL template based on
the deformation fields produced in the segmentation procedure in
which all individual deformation fields are warped (and modulat-
ed) to match this template [32]. Images were smoothed using a 8-
mm, full-width-at-half-maximum Gaussian kernel to increase the
signal-to-noise ratio, with each voxel of the resulting grey and
white matter images representing the absolute amount of grey and
white matter volume equivalent to their volume per unit before
normalization [32].
Image Data Analyses
Absolute total grey and white matter volumes were calculated
using the native space grey and white matter segmentations.
Smoothed grey and white matter density images were used in the
voxel-wise regression analyses with fasting blood glucose levels as
predictor. To account for the effects of possible confounding
factors age, gender, BMI, depression and alcohol consumption
were controlled for. Results were assessed at a=0.0005.
Statistical Analyses
Demographic characteristic analyses were conducted using IBM
SPSS Statistics 20.0. After testing whether blood glucose levels in
the normal range were associated with regional grey and white
matter volumes, we next tested whether these glucose-related
regional cluster volumes were associated with cognitive test
performance. Grey and white matter regional volumes at
significant voxels were extracted at the cluster level using the
SPM8 ‘‘eigenvariate’’ extraction tool and standardized to Z-scores.
In accordance with the literature [33,34], and due to the
nonparametric distribution of cognitive test performance, Spear-
man’s Rank Order correlations was used to assess the association
between the glucose-related regional volumes and cognitive test
performance. Missing data for cognitive measures were imputed
using the EM algorithm.
Results
Participants’ demographic characteristics are presented in
Table 1.
Associations between fasting glucose levels and regional
brain volumes
Voxelwise analyses using continuous blood glucose levels as a
predictor while controlling for age, gender, BMI, depression and
alcohol consumption showed higher ‘normal’ plasma glucose levels
to be associated with decreased regional grey (L Middle Frontal
Gyrus, R Inferior Frontal Gyrus (Pars Triangularis), L Precentral
Gyrus) and white matter (R Inferior Frontal Gyrus, Pars
Triangularis) regional volumes (Table 2). Higher ‘normal’ blood
glucose levels were notably associated with lower grey matter
regional volumes in the left hemisphere and lower white matter
regional volumes in the right hemisphere (Figure 2).
Volume-Cognition Relationships
Table 3 presents the associations between cognitive perfor-
mance on individual tests and glucose-related regional grey/
white matter volumes. Spearman’s Rank Order correlations
determined a significant positive association between grey matter
regional volumes and a number of cognitive functions. Specif-
ically, a positive correlation was found between the Left Middle
Frontal Gyrus (Region 2) and raw scores on the DBS
(rs= .158, p= .022), SDMT (rs= .207, p= .003), COWAT-F
words (rs= .173, p= .012), COWAT-A words (rs= .172,
p= .013) and BNT (rs= .173, p= .012). A positive correlation
was also found between the Right Inferior Frontal Gyrus
(Region 3) and raw scores on the DBS (rs= .193, p= .005).
Furthermore, significant positive correlations were found between
the Left Middle Frontal Gyrus (Region 4) and raw scores
on the DBS (rs= .184, p= .007), and BNT (rs= .152, p= .027). It
should be noted that a trend was also observed between the Left
Middle Frontal Gyrus and performance on the COWAT-A
words (rs= .135, p= .051). A further trend was also observed
between white matter regional volumes of the R Inferior
Frontal Gyrus (Region 5) and performance on the DBS
(rs= .133, p= .054). No significant associations were found
between cognitive performance and grey matter regional volumes
in L Precentral Gyrus (Region 1).
Interestingly, this study found the association between grey
matter regional volumes and cognitive function to be gender
specific. In men, small to medium effects were found between grey
matter regional volumes in the Left Middle Frontal Gyrus
(Region 2) and raw scores on the SDMT (rs = .256, p = .007),
COWAT-F words (rs= .202, p= .033), and BNT (rs= .192,
p= .043); between the Right Inferior Frontal Gyrus (Region
3) and DBS (rs = .190, p = .046), COWAT-F words (rs= .207,
p= .030), and COWAT-A words (rs = .198, p = .037). Small to
medium effects were also found between grey matter regional
volumes of the Left Middle Frontal Gyrus (Region 4) and
raw scores on the IRT (rs = .222, p= .019), and BNT (rs = .190,
p = .045). In men, white matter regional volumes of the RMiddle
Frontal Gyrus (Region 5) were not associated with cognitive
performance.
In women, grey matter regional volumes in the Left Middle
Frontal Gyrus (Region 2) were only associated with raw
scores on the SDMT (rs= .248, p= .013). Notably, in women, a
negative trend was observed between the Right Inferior Frontal
Gyrus and performance on the COWAT-F words (rs=2.192,
p= .056).
Sensitivity Analyses
To determine whether the observed effects of normal blood
glucose levels are modulated by diabetes, analyses were also
conducted with all participants with a blood glucose level in the
normal range (,6.1 mmol/L), including those reporting a history
of diabetes (n = 231). The results followed the same pattern as that
presented above.
Discussion
This study investigated the association between normal blood
glucose levels and grey and white matter regional volumes across
the whole brain and its association with cognitive performance in a
large, community-based sample of cognitively healthy individuals
without diabetes, glucose intolerance or metabolic syndrome.
Three important findings were made: 1) higher glucose levels in
the normal range were associated with lower grey and white
matter regional volumes; 2) lower glucose-related grey/white
PATH: High Normal Blood Glucose and the Brain
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matter regional volumes were associated with poorer cognitive
performance; 3) structure-function associations were gender
specific.
In voxel-wise analyses high-normal blood glucose levels were
associated with lower grey and white matter regional volumes in
the frontal cortices – areas associated with increased age-related
Table 1. Wave 3 PATH Sample Descriptive.
Characteristics
Overall Sample
(N=210) Male Female F/x2
(N=111) (N=99) male vs. female
Age, years (SD) 70.4 (1.42) 70.4 (1.42) 70.5 (1.42) .231
Range 68–73 68–73 68–73
Race .456
Caucasian, N (%) 201 (95.7) 106 (95.5) 95 (95.9)
Asian, N (%) 4 (1.9) 2 (1.8) 2 (2.02)
Other, N (%) 3 (1.4) 1 (0.9) 2 (2.02)
Education, years (SD) 14.4 (2.58) 15.3 (2.23) 13.4 (2.59) 31.9***
Range 5–19 11–19 5–19
MMSE, score (SD) 29.4 (.876) 29.3 (.929) 29.5 (.800) 3.74
Range 26–30 26–30 26–30
BMI, score (SD) 26.1 (4.74) 26.1 (3.53) 25.9 (5.82) .028
Range 18–60 20–37 18–60
Average Blood Glucose, level (SD) 4.91 (.571) 4.99 (.509) 4.83 (.626) 4.15*
Range 3.2–6.1 3.4–6.0 3.2–6.1
Alcohol Consumption 19.3**
Abstain, N (%) 13 (6.2) 5 (4.51) 8 (8.08)
Occasional, N (%) 26 (12.4) 7 (6.31) 19 (19.2)
Light, N (%) 110 (52.4) 72 (64.9) 38 (38.4)
Medium, N (%) 45 (21.4) 18 (16.2) 27 (27.3)
Hazardous, N (%) 12 (5.7) 7 (6.31) 5 (5.05)
Harmful, N (%) 1 (0.5) 0 (0) 1 (1.01)
Smoke 1.98
History or Current, N (%) 87 (41.4) 51 (45.9) 36 (36.4)
Depression .840
No Depression, N (%) 192 (91.4) 102 (91.9) 90 (90.9)
Subsyndromal Depression, N (%) 12 (5.7) 5 (4.51 7 (7.07)
Minor Depression, N (%) 2 (1.0) 1 (0.90) 1 (1.01)
Major Depression, N (%) 3 (1.4) 2 (1.8) 1 (1.01)
Cognitive Test Performance
Immediate Recall, mean (SD) 7.06 (2.07) 6.64(1.77) 7.53 (2.27) 10.0**
Range 2–13 3–11 2–13
Delayed Recall, mean (SD) 6.22 (2.23) 5.87 (1.93) 6.62 (2.47) 5.94**
Range 0–12 2–11 0–12
Digit Span Backwards, mean (SD) 5.39 (2.07) 5.85 (2.04) 4.87 (1.99) 12.3***
Range 1–10 1–10 1–10
Symbol Digit Modalities mean (SD) 49.9 (8.34) 49.9 (7.94) 49.9 (8.81) .000
Range 16–71 27–66 16–71
COWAT F-words, mean (SD) 14.5 (4.97) 15.0 (4.95) 13.9 (4.94) 2.29
Range 4–31 7–31 4–30
COWAT A-words, mean (SD) 13.0 (5.45) 13.8 (5.35) 12.2 (5.47) 4.18*
Range 0–30 2–30 0–29
Boston Naming Test, mean (SD) 13.8 (1.29) 13.9 (1.18) 13.7 (1.39) 2.09
Range 9–15 10–15 9–15
*p,.05 ** p,.01 *** p,.001.
doi:10.1371/journal.pone.0073697.t001
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decline and episodic memory impairments (e.g. executive function)
[35,36]. In particular, high-normal blood glucose levels were
found to be associated with lower regional grey matter volumes in
the left middle frontal gyrus, right inferior frontal gyrus (Pars
Triangularis) and the left precentral gyrus and lower regional
white matter regional volumes in the right inferior frontal gyrus.
Notably, the predominant left hemisphere findings observed in
relation to higher-normal blood glucose levels in our study are
consistent with previous research demonstrating higher left
hemisphere vulnerability in pathological ageing [37]. In Alzhei-
mer’s disease, frontal regions are disproportionately atrophic (after
brain size correction) with greater left versus right hemisphere
atrophy observed [38]. These findings are of particular interest as
evidence suggests that diabetes is associated with greater amyloid
plaque deposition and greater cerebro-vascular damage, which
forms the anatomical basis for clinical and subclinical cognitive
impairment [6,8]. The present findings suggest a similar pattern of
lower grey/white matter regional volumes in the pre-frontal and
frontal cortices consistent with those found in individuals prior to
the onset of dementia [38].
Importantly, this study found that smaller regional volumes
associated with high-normal blood glucose levels were linked to
Figure 2. Sagittal, Coronal and Axial Representations of Glucose-related Regional Grey (A) and White (B) Matter Volumes.
doi:10.1371/journal.pone.0073697.g002
Table 2. Atlas Coordinates, Cluster Extents, P and T Values and Regional Descriptions.
MNI coordinates (x, y, z) Cluster extent (k)
Cluster-level
P uncorrected T Region description (for cluster peak)
Grey Matter
Region 1 242, 8 39 113 ,0.0005 3.85 Left Precentral Gyrus
Region 2 222, 45, 25 59 ,0.0005 3.63 Left Middle Frontal Gyrus
Region 3 42, 27, 28 20 ,0.0005 3.77 Right Inferior Frontal Gyrus (Pars Triangularis)
Region 4 233, 60, 16 66 ,0.0005 3.97 Left Middle Frontal Gyrus
White Matter
Region 5 48, 32, 19 21 ,0.0005 3.80 Right Inferior Frontal Gyrus (Pars Triangularis)
doi:10.1371/journal.pone.0073697.t002
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poorer cognitive performance. Specifically, smaller regional
volumes appeared to be associated with poorer working memory,
executive functions, information and processing speed, and
language function. These findings are in accordance with
literature linking both subclinical [9] and diabetic glucose levels
[39] to cognitive performance but extend them by showing that
this association is also present in what is considered plasma
glucose’s normal range (up to 6.1 mmol/L). Future research
should consider the possible impact of these findings in terms of
glucoregulation in the ‘higher-normal’ range and its relationship
with memory performance, as increased metabolic demand during
regional activation (i.e. memory testing) may be associated with
regional low-grade hypoglycaemia and ultimately an inability to
compensate for drops in glucose levels during the activation of
these circuits during memory testing [10].
Finally, the association between glucose-related regional
volumes and cognitive test performance were gender specific.
For women, only smaller grey matter regional volumes of the left
middle frontal gyrus were significantly associated with information
and processing speed, a process shown to be impaired in women
with type 2 diabetes [39]. However, for men, smaller grey matter
regional volumes were significantly associated with poorer
information and processing speed, episodic memory, and execu-
tive function, while smaller white matter regional volumes were
associated with poorer language function. These findings raise
interesting questions regarding gender specific impact of normal
blood glucose levels on cerebral structure and cognitive perfor-
mance in healthy individuals in their 60 s. Research has shown the
incidence of Alzheimer’s disease to be consistently higher in
women and the incidence of Vascular Dementia to be consistently
higher in men [40]. Such gender differences may be due to
biological, survival or cohort differences in the exposure to
protective or risk factors [40]. The protective role of estrogens,
cardiovascular disease and survival rates may provide an
explanation for the current findings. A better understanding of
the impact of higher blood glucose levels in the normal range on
cardiovascular disease in men may provide further insight into the
gender-specific association of grey and white matter regional
volumes and cognitive performance in the current study.
It is important to consider possible mechanisms which may
underpin the association between blood glucose levels, vascular
variations, regional volumes (e.g. atrophy) and cognitive change.
Possible mechanisms proposed to be involved include inflamma-
tory processes [12], as research has linked experimentally raised
Table 3. The relationship between regional brain volumes and cognitive test performance.
Cognitive Test
IRT DRT DSB SDMT COWAT F COWAT A BNT
Overall Sample
Grey Matter
Region 1 (L Precentral Gyrus) .033 .016 .094 .057 .101 .046 .112
Region 2 (L Middle Frontal Gyrus) 2.049 2.054 .158* .207** .173* .172* .173*
Region 3 (R Inferior Frontal Gryus) 2.066 2.035 .193** .069 .099 .097 .073
Region 4 (L Middle Frontal Gyrus) 2.082 2.065 .184** .066 .127 .1351 .152*
White Matter
Region 5 (R Inferior Frontal Gyrus) 2.043 2.085 .1331 .094 .032 .057 .044
Male
Grey Matter
Region 1 (L Precentral Gyrus) .158 .096 .078 2.024 .052 .052 .127
Region 2 (L Middle Frontal Gyrus) .159 .053 .079 .256** .202* .108 .192*
Region 3 (R Inferior Frontal Gryus) .047 .028 .190* .154 .207* .198* .157
Region 4 (L Middle Frontal Gyrus) .222* .171 .156 .098 .164 .140 .190*
White Matter
Region 5 (R Inferior Frontal Gyrus) .080 2.044 .010 .097 .172 .108 .084
Female
Grey Matter
Region 1 (L Precentral Gyrus) .053 .060 2.051 .166 .122 2.024 .059
Region 2 (L Middle Frontal Gyrus) .020 .045 2.006 .248* .160 .165 .114
Region 3 (R Inferior Gryus) 2.016 .004 .046 .018 .003 2.026 2.065
Region 4 (L Middle Frontal Gyrus) 2.116 2.121 2.014 .071 .024 2.002 .057
White Matter
Region 5 (R Inferior Frontal Gyrus) 2.005 2.038 .083 .078 2.1922 2.085 2.094
Abbreviations: IRT: California Verbal Learning Test for Immediate Recall, DRT: California Verbal Learning Test for Delayed Recall, DSB: Digit Span Backwards from the
Wechsler Memory Scale, SDMT: Symbol-Digit Modalities Test, COWAT-A/COWAT-F Controlled Oral Word Association Test for A- and F-words, BNT: Boston Naming Test.
1 p-value approaching significance (i.e. p = .054 and p= .051).
2 p-value approaching significance (i.e. p = .056).
**p,.01.
*p,.05.
doi:10.1371/journal.pone.0073697.t003
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glucose levels with increased plasma cytokine levels (tumor
necrosis factor-a, interleukin-6 and interleukin-10) in healthy
individuals and those with impaired glucose tolerance [16].
Furthermore, this study by Esposito et al. [16] found that
inflammatory reactions peaked higher and lasted longer in IGT
subjects, indicating that control of plasma glucose levels modulates
systemic inflammatory responses and that individuals with type 2
diabetes are therefore more likely to be exposed to longer and
stronger inflammatory states [12]. As chronic systemic inflamma-
tion has been linked to cerebral atrophy, it is therefore also
plausible that blood glucose levels in the higher normal range may
also be associated with neurodegeneration [12]. The current
findings provide further evidence of this association.
Furthermore, research has linked coagulation-related abnor-
malities to type 2 diabetes (i.e. raised tissue factor, factor VII, (pro-
)thrombin, fibrinogen levels) [41]. Darvall and colleagues [42]
have linked such alterations to abnormal clotting and greater
cardiovascular events and the activation of prothrombic pathways
have also been associated with poorly regulated blood glucose
levels in prediabetic states (e.g. insulin resistance, metabolic
syndrome) [12]. As prediabetic states (e.g. metabolic syndrome,
insulin resistance) have been linked to an increased risk of
thrombosis [43], it is therefore possible that high glucose levels in
the absence of type 2 diabetes may result in abnormal coagulation
function, therefore increasing the risk of thrombosis, microemboli
and clinical and subclinical strokes – all which are known risk
factors of cerebral brain ageing [12].
It should also be noted that psychological stressors have also
been associated with an higher risk of type 2 diabetes, with
depressive individuals having been found to have a 60% increased
risk of diabetes [44]. As noted, chronic stress is associated with
increased hypothalamic-pituitary-adrenal (HPA) axis activation,
which in turn is also associated with higher glucose levels [19]. It is
therefore plausible that stressors may contribute to higher glucose
levels and associated brain effects [12]. While not focused on the
mechanisms underpinning the association between glucose levels,
regional brain volumes and cognition, our findings contribute to
the existing understanding and provide further evidence for an
association between what is considered to be ‘normal’ blood
glucose levels, cerebral integrity and cognition.
This study had a number of limitations but also several
strengths. First, while PATH is a population representative study
in which participants were randomly selected into the neuroim-
aging sub-study from the larger population-representative cohort,
it may not be completely representative of the population at
large. Moreover, the selection procedure which excluded those
with pre-clinical or diagnosed diabetes, neuro-cognitive disorders
and brain abnormalities further decreased the representativeness
of the sample. However, the overall effect of this methodology
was to select overall healthier individuals and therefore any effect
detected in this study is likely to be an underestimate of those
applying to the general population. Secondly, while the use of a
narrow age cohort avoids some biases due to cohort effect and
therefore allows for more sensitive detection of associations
between normal blood glucose, structural brain volumes and
cognitive performance, it may also make it more difficult to
generalize the current findings to other age groups. Thirdly,
although a widely accepted WHO cut-off level for normal blood
glucose (,6.1 mmol/L) was used, it must be noted that cut-offs
for normality are being debated and the American Diabetes
Association has already adopted a normal fasting level of
,5.6 mmol/L. Fourthly, the assessment of plasma glucose at
solely one time point provides a further limitation of this study.
As plasma glucose levels are known to fluctuate, this single
observation of glucose levels may not be truly representative of
the on-going glucose state of an individual. Future studies, where
possible, should include assessments of HBA1c levels – a measure
of average blood glucose control over 2–3 months – to obtain a
more representative measure. Finally, it must be noted that while
blood glucose levels were assessed following a minimum of
10 hours fasting, there are many factors which may contribute to
variations in glucose levels. For example, it is known that blood
glucose levels progressively increase across the adult lifespan and
that cognition tends to decrease with age, especially in old age.
Therefore, associations between blood glucose and cognition may
be detected not due to direct associations but due to their
association with age. To minimise possible confounding effect of
age, the current study used a narrow age cohort design (4 year
age range) and also controlled for age in the statistical analyses. It
is therefore unlikely that age effects explain the findings reported
in the current study. BMI is also a likely confounding factor as
obesity is associated with increased caloric intake, higher risk of
insulin resistance, greater cerebral atrophy and cognitive decline.
To minimise possible confounding effects, the current study
controlled for BMI. However, effects due to BMI may not have
been completely accounted for and could potentially explain
some of our findings. Further, it is also known that depression
contributes to poorer cognition in diabetes. While this study
controlled for depression to minimise possible confounding
effects, it is possible that effects due to depression may not have
been completely accounted for and that these could potentially
also explain some of our findings. Other factors which are
potential confounders, but which are less relevant to the studied
population, include medications (e.g. corticosteroids, diuretics,
epinephrine, estrogen, glucagon, lithium and antidepressants),
medical conditions (e.g. chronic renal failure, Cushing’s syn-
drome, over or under active thyroid, pancreatic cancer, adrenal
insufficiency, liver disease, underactive pituitary gland), activation
of the stress response, the type and quantities of food eaten, and
drug use (e.g. acetaminophen, alcohol, anabolic steroids,
monoamine oxidase inhibitors and pentamidine). Notably, these
confounds may not only impact the accuracy of the glucose
readings, but may also independently impact brain structure and
cognitive function.
Despite these limitations, this study is characterized by
significant strengths. First, its large sample size makes this study
significantly more representative of the population than others
described in the diabetic literature (mainly self-selected and clinical
samples). Secondly, the exclusion of individuals with diabetes, sub-
clinical diabetes or glucose intolerance based on the World Health
Organisation threshold for impaired fasting hyperglycaemia
(6.1 mmol/L, 110 mg/dl) ensured that the effects detected were
not due to clinical or sub-clinical glucose metabolism abnormal-
ities. Thirdly, to ensure the effects detected related to normal
blood glucose levels, individuals with other neurological disorders
were excluded. This allowed for the investigation of long term
associations between normal blood glucose levels, brain structure
and cognitive performance despite a cross-sectional design. In
conclusion, the current findings stress the need to re-evaluate what
is considered healthy blood glucose levels, investigate possible
mechanisms contributing to a possible modulating effect between
normal blood glucose levels and pathological change, and consider
the role of higher normal blood glucose levels as a risk factor for
cerebral health, cognitive function and dementia. A better lifetime
management of blood glucose levels may ultimately contribute to
improved old age memory and possibly have a protective effect
against cognitive impairments.
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